(Q39639310)

13 September 2017

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling (English)

1 reference

13 September 2017

1 reference

1 reference

L de Zwart

1

1 reference

13 September 2017

J Snoeys

2

1 reference

13 September 2017

J De Jong

3

1 reference

13 September 2017

J Sukbuntherng

4

1 reference

13 September 2017

E Mannaert

5

1 reference

13 September 2017

M Monshouwer

6

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 July 2016

1 reference

Clinical Pharmacology & Therapeutics

13 September 2017

1 reference

13 September 2017

100

1 reference

13 September 2017

5

1 reference

13 September 2017

548-557

1 reference

Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

13 September 2017

1 reference

Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.

21 January 2018

1 reference

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults

21 January 2018

1 reference

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

21 January 2018

1 reference

Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations

21 January 2018

1 reference

Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.

21 January 2018

1 reference

Correlation between the systemic clearance of drugs and their food effects in humans.

21 January 2018

1 reference

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

21 January 2018

1 reference

Use of intrinsic clearance for prediction of human hepatic clearance

21 January 2018

1 reference

Reassessing models of hepatic extraction

21 January 2018

1 reference

Prediction of hepatic clearance in human from in vitro data for successful drug development

21 January 2018

1 reference

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole

21 January 2018

1 reference

Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.

21 January 2018

1 reference

Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.

21 January 2018

1 reference

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

21 January 2018

1 reference

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

21 January 2018

1 reference

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.

21 January 2018

1 reference

Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19

21 January 2018

1 reference

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation

21 January 2018

1 reference

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

21 January 2018

1 reference

pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development

21 January 2018

1 reference

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th

21 January 2018

1 reference

Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?

21 January 2018

1 reference

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

21 January 2018

1 reference

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

21 January 2018

1 reference

Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs

21 January 2018

1 reference

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

21 January 2018

1 reference

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

21 January 2018

1 reference

Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.

21 January 2018

1 reference

Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A

21 January 2018

1 reference

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

21 January 2018

1 reference

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.

21 January 2018

1 reference

Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies

21 January 2018

1 reference

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males

21 January 2018

1 reference

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

Population pharmacokinetic model of PI-88, a heparanase inhibitor

21 January 2018

1 reference

Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients

21 January 2018

1 reference

Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.

21 January 2018

1 reference

Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer

21 January 2018

1 reference

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

21 January 2018

1 reference

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

21 January 2018

1 reference

Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CPT.419

1 reference

13 September 2017

1 reference